Search for new products by date added, alphabetically, or by pharmacological action.
New products are an essential component of our range. Introductions are made on an ongoing basis, with hundreds of new small molecules and peptides being added every year. Our aim is to find the latest, otherwise unobtainable research tools, and bring them to the market as quickly as we can. New products can be identified throughout the Tocris website by the New symbol.
If you can't find what you are looking for we welcome new product suggestions. If you would like to be kept informed about new products by email, please sign up for our monthly e-alert service.
| Cat No | Product Name / Activity | Date Added |
|---|---|---|
| 6167 | A 196 | Jul 2017 |
| Potent and selective SUV420H1/H2 inhibitor | ||
| 6165 | AC 265347 | Jul 2017 |
| CaSR biased allosteric modulator | ||
| 5879 | ACES | Feb 2017 |
| Zwitterionic buffer | ||
| 5758 | AGN 193109 | Mar 2017 |
| High affinity pan-RAR antagonist | ||
| 6193 | AM 4113 | Aug 2017 |
| Selective, high affinity CB1 antagonist | ||
| 6086 | AMP PNP | Mar 2017 |
| Kir6 blocker; non-hydrolyzable AMP analog | ||
| 5658 | AR-C 141990 hydrochloride | Jul 2017 |
| MCT1 inhibitor | ||
| 5720 | AR-C 69931 tetrasodium salt | Mar 2017 |
| Highly potent P2Y12 antagonist | ||
| 5872 | AZ 10397767 | Mar 2017 |
| Potent CXCR2 antagonist | ||
| 5675 | AZ PFKFB3 26 | May 2017 |
| Potent and selective PFKFB3 inhibitor | ||
| 6060 | AZD 2461 | May 2017 |
| Potent PARP inhibitor; orally bioavailable | ||
| 6161 | Ailanthone | Apr 2017 |
| Potent inhibitor of androgen receptor (AR) | ||
| 6219 | Arformoterol tartrate | Apr 2017 |
| Long-acting β2 agonist (LABA) | ||
| 6009 | B I09 | Apr 2017 |
| IRE1 endonuclease inhibitor; cell permeable | ||
| 6116 | BHPI | Aug 2017 |
| ERα antagonist; also activates unfolded protein response; active in vivo | ||
| 5300 | BI 605906 | Mar 2017 |
| Selective IKKβ inhibitor | ||
| 6047 | BOP | Mar 2017 |
| Dual α9β1/α4β1 integrin inhibitor; preferentially mobilizes HSCs | ||
| 6078 | BPTU | Jul 2017 |
| P2Y1 allosteric antagonist | ||
| 6282 | BRD 4770 | Jun 2017 |
| G9a inhibitor and S-adenosyl methionine mimetic; cell permeable | ||
| 6284 | BRD 73954 | Jun 2017 |
| Dual histone deacetylase (HDAC) 6/8 inhibitor | ||
| 5881 | Bicine | Feb 2017 |
| General purpose buffer | ||
| 6304 | BigLEN (mouse) | Jul 2017 |
| GPR171 agonist | ||
| 6306 | BigLEN (rat) | Jul 2017 |
| Potent GPR171 agonist | ||
| 5372 | Bioymifi | May 2017 |
| DR5 (TRAIL receptor) agonist; induces apoptosis | ||
| 6232 | Bosentan | Mar 2017 |
| High affinity dual ETA and ETB receptor antagonist;orally bioavailable | ||
| 6196 | Brequinar sodium | Aug 2017 |
| Potent and selective dihydroorotate dehydrogenase (DHODH) inhibitor | ||
| 5821 | C-DIM 12 | May 2017 |
| Nurr1 activator; inhibits NF-κB-dependent gene expression | ||
| 5873 | CAPS | Feb 2017 |
| Buffer widely used in Western blotting | ||
| 6258 | CC 401 dihydrochloride | May 2017 |
| High affinity JNK inhibitor; also inhibits HCMV replication | ||
| 5963 | CMPI hydrochloride | May 2017 |
| Potent positive allosteric modulator of α4β2 nAChRs; also inhibitor of (α4)2(β2)3, muscle-type and Torpedo nAChRs | ||
| 6107 | CP 424174 | Mar 2017 |
| Inhibitor of IL-1β post-translational processing; indirectly inhibits NLRP3 | ||
| 6174 | CVT 313 | Jun 2017 |
| cdk2 inhibitor | ||
| 6264 | Caerulein | Mar 2017 |
| CCK agonist | ||
| 6170 | Cinacalcet hydrochloride | Feb 2017 |
| Calcium-sensing receptor (CaSR) allosteric agonist; also CYP2D2 inhibitor and Ca2+ channel blocker; orally bioavailable | ||
| 5435 | Cyanine 3, SE | Mar 2017 |
| Orange fluorescent dye for labeling of amines | ||
| 5437 | Cyanine 7, SE | Mar 2017 |
| Near-infrared fluorescent dye for labeling of amines | ||
| 5921 | D9 | May 2017 |
| Potent thioredoxin reductase (TrxR) inhibitor | ||
| 6175 | DBHDA | Apr 2017 |
| Reagent for synthetic biology; converts cysteine to dehydroalanine | ||
| 6231 | Dacomitinib | Jul 2017 |
| Potent irreversible pan ErbB inhibitor | ||
| 6277 | 7α,25-Dihydroxycholesterol | Jun 2017 |
| Highly potent GPR183 (EBI2) agonist | ||
| 6292 | ELARR>GG | Jul 2017 |
| Negative control for ELA-32 (Cat.No.6291). | ||
| 6293 | ELA-14 (human) | Jun 2017 |
| Potent apelin (APJ) receptor agonist | ||
| 6294 | ELA-14 negative control | Jun 2017 |
| Negative control for ELA-14 (Cat.No.6293). | ||
| 6291 | ELA-32 (human) | Jul 2017 |
| Potent, high affinity apelin receptor agonist; stimulates angiogenesis | ||
| 6234 | Entecavir | Apr 2017 |
| Potent and selective hepatitis B virus inhibitor | ||
| 6158 | (S)-Equol | May 2017 |
| Potent estrogen receptor β (ERβ) agonist; dihydrotestosterone antagonist | ||
| 6204 | 7-Ethoxyresorufin | Mar 2017 |
| Fluorometric CYP450 substrate | ||
| 6188 | Everolimus | Apr 2017 |
| mTOR inhibitor;immunosuppressant | ||
| 6253 | F 127 (20% solution in DMSO) | Apr 2017 |
| Nonionic detergent | ||
| 6176 | FTY 720 | Feb 2017 |
| Potent S1P receptor agonist; also immunosuppressant | ||
| 6100 | Fasentin | May 2017 |
| GLUT1/GLUT4 inhibitor; also Fas-sensitizer | ||
| 6250 | Filipin III | Mar 2017 |
| Polyene antibiotic; inhibits formation of pathological isoform of prion protein | ||
| 5407 | GA3-AM | Mar 2017 |
| Gibberellin-analog (GA3) chemical dimerizer; cell permeable | ||
| 5672 | GSK 319347A | Feb 2017 |
| Potent and selective IKKε inhibitor | ||
| 6128 | GSK 343 | Jun 2017 |
| Potent and selective SAM-competitive EZH2 inhibitor | ||
| 6218 | Galiellalactone | Apr 2017 |
| STAT3 inhibitor; active in vivo | ||
| 6211 | H3K27(Me) (15-34) | Apr 2017 |
| Histone H3 peptide; substrate for demethylase/methyltransferase enzymes | ||
| 6212 | H3K27(Me2) (15-34) | Apr 2017 |
| Histone H3 peptide; substrate for methyltransferase/demethylase enzymes | ||
| 6213 | H3K27(Me3) (15-34) | Apr 2017 |
| Histone H3 peptide; substrate for methyltransferase/demethylase enzymes | ||
| 6214 | H3K4(Me) (1-20) | Apr 2017 |
| Histone H3 peptide; substrate for methyltransferase/demethylase enzymes | ||
| 6215 | H3K4(Me2) (1-20) | May 2017 |
| Histone H3 peptide | ||
| 6216 | H3K4(Me3) (1-20) | Apr 2017 |
| Histone H3 peptide; substrate for methyltransferase/demethylase enzymes | ||
| 5850 | HM 50316 | Feb 2017 |
| High affinity FABP4 inhibitor | ||
| 5768 | HS 38 | Jul 2017 |
| ATP-competitive inhibitor of DAPK and ZIPK | ||
| 6217 | Histone H3 (1-34) | Apr 2017 |
| Histone H3 peptide | ||
| 5741 | 25-Hydroxycholesterol | Apr 2017 |
| Antiviral; also α-crystallin (cryAB) chaperone | ||
| 6016 | IN 1130 | Jul 2017 |
| Potent and selective inhibitor of TGF-βRI | ||
| 5846 | IT 901 | Feb 2017 |
| NF-κB c-Rel subunit inhibitor | ||
| 4322 | JH 295 | May 2017 |
| Irreversible Nek2 inhibitor | ||
| 6289 | JH-II-127 | Aug 2017 |
| Potent and selective LRRK2 inhibitor | ||
| 6278 | JNJ 55511118 | Aug 2017 |
| Selective, high affinity negative modulator of AMPA receptors containing TARP-γ8 | ||
| 5865 | KLH 45 | Mar 2017 |
| Potent DDHD2 inhibitor | ||
| 6146 | LAP | Mar 2017 |
| Photocrosslinker for hydrogels | ||
| 6151 | LDN 212854 | Apr 2017 |
| Potent bone morphogenetic protein type I (ALK) inhibitor | ||
| 6152 | LDN 214117 | Apr 2017 |
| Potent and selective ALK2 inhibitor | ||
| 5826 | LEI 101 hydrochloride | May 2017 |
| Potent and selective CB2 partial agonist; orally biovailable | ||
| 6098 | Lalistat 1 | Aug 2017 |
| Potent and selective lysosomal acid lipase (LAL) inhibitor | ||
| 3974 | Latrunculin B | May 2017 |
| Inhibitor of actin polymerization | ||
| 6305 | Lenalidomide | Jun 2017 |
| Cereblon binder; induces ubiquitination and degradation of CK1α by E3 ubiquitin ligase | ||
| 6265 | Lonafarnib | Jul 2017 |
| Potent farnesyl transferase inhibitor | ||
| 5103 | Lys-CoA | Jun 2017 |
| Selective p300 inhibitor | ||
| 5705 | M62812 | Aug 2017 |
| TLR-4 inhibitor | ||
| 5785 | MDNI-caged-L-glutamate | Feb 2017 |
| Stable photoreleaser of L-glutamate | ||
| 5842 | MK 386 | May 2017 |
| Potent, selective human type 1 5α-reductase inhibitor | ||
| 5987 | (±)-ML 209 | Apr 2017 |
| RORγt inverse agonist; suppresses Th17 cell differentiation | ||
| 5700 | ML 315 hydrochloride | Apr 2017 |
| Inhibitor of Clk and DYRK kinases | ||
| 6171 | MLS 1547 | Mar 2017 |
| G protein-biased D2 receptor partial agonist | ||
| 5888 | MOPSO, free acid | May 2017 |
| Buffer; working pH range in aqueous solution: 6.2-7.6 | ||
| 6299 | MS 15203 | Aug 2017 |
| Potent and selective GPR171 partial agonist | ||
| 6208 | MS 275 | Jun 2017 |
| HDAC (Class I) inhibitor | ||
| 6154 | MZ 1 | Apr 2017 |
| (+)-JQ1 based PROTAC that selectively degrades BRD4 in cells | ||
| 6285 | Megestrol Acetate | May 2017 |
| Synthetic progesterone analog | ||
| 6189 | Myricetin | Jun 2017 |
| Irreversible TrxR inhibitor | ||
| 5986 | NAV 2729 | Feb 2017 |
| Selective ARF6 inhibitor | ||
| 6121 | NB-caged Tyrosine hydrochloride | May 2017 |
| ortho-nitrobenzyl caged L- tyrosine | ||
| 5150 | NCL 00017509 | May 2017 |
| Potent and reversible NIMA related kinase 2 (Nek2) inhibitor | ||
| 6045 | NITD 008 | Jul 2017 |
| Antiviral; selective flavivirus inhibitor | ||
| 6180 | NMS 873 | Apr 2017 |
| Potent and selective p97 ATPase (VCP) allosteric inhibitor | ||
| 5818 | NVP BSK 805 | Aug 2017 |
| Potent JAK2 inhibitor; orally bioavailable | ||
| 6183 | Nanchangmycin | May 2017 |
| Antiviral; active against Zika, West Nile and dengue viruses | ||
| 5976 | Ned K | Apr 2017 |
| NAADP signaling inhibitor | ||
| 6119 | OB 24 hydrochloride | Aug 2017 |
| Potent and selective heme oxygenase 1 (HO-1) inhibitor | ||
| 6181 | OTX 015 | May 2017 |
| BET bromodomain inhibitor; orally bioavailable | ||
| 6012 | OXSI 2 | May 2017 |
| Potent Syk kinase inhibitor; also inhibits assembly of NLRP3 inflammasomes | ||
| 6073 | P21d hydrochloride | Jun 2017 |
| Potent and selective Brk inhibitor | ||
| 6149 | PA Janelia Fluor® 549, SE | Apr 2017 |
| Photoactivatable cell permeable fluorescent dye; supplied as NHS ester | ||
| 6150 | PA Janelia Fluor® 646, SE | Apr 2017 |
| Photoactivatable cell permeable fluorescent dye; supplied as NHS ester | ||
| 5419 | PCNA I1 | Feb 2017 |
| PCNA inhibitor | ||
| 6049 | PF 04937319 | Aug 2017 |
| Glucokinase partial activator | ||
| 6221 | PKI (5-24) | Mar 2017 |
| High affinity PKA inhibitor | ||
| 6303 | Parathyroid hormone (1-34) (bovine) | Jun 2017 |
| Parathyroid hormone (PTH) receptor agonist. | ||
| 6301 | Parathyroid hormone (1-34) (rat) | Jun 2017 |
| Parathyroid hormone (PTH) receptor agonist | ||
| 6185 | Pemetrexed | Jun 2017 |
| High affinity dihydrofolate reductase inhibitor; also inhibits thymidylate synthase, GARFT and AICART | ||
| 6288 | Peptide YY (3-36) human | Jun 2017 |
| NPY Y2 receptor agonist | ||
| 6302 | Pomalidomide | Jun 2017 |
| Cereblon ubiquitination inhibitor; also TNFα inhibitor and antiangiogenic | ||
| 6317 | Prasugrel | Jul 2017 |
| Irreversible P2Y12 antagonist; antiplatelet and orally active | ||
| 6048 | R-BC154 | Aug 2017 |
| High affinity fluorescent α4β1 /α9β1 inhibitor; mobilizes HSCs | ||
| 6259 | RAGE antagonist peptide | May 2017 |
| Receptor for advanced glycation end products (RAGE) antagonist | ||
| 6168 | RI 1 | Apr 2017 |
| RAD51 recombinase inhibitor | ||
| 6233 | Retigabine | Mar 2017 |
| KV7 channel activator | ||
| 6190 | Retrobradykinin | Apr 2017 |
| Reverse analog of Bradykinin | ||
| 6230 | Rucaparib camsylate | Aug 2017 |
| PARP inhibitor | ||
| 6088 | SB 3CT | Feb 2017 |
| Selective high affinity MMP2 inhibitor | ||
| 6164 | SEA 0400 | Apr 2017 |
| Potent Na+/Ca2+ exchanger (NCX) inhibitor. | ||
| 6101 | SHIP 2a | Feb 2017 |
| Cystathione γ lyase (CSE) inhibitor | ||
| 5452 | SKI 178 | May 2017 |
| Non-lipid sphingosine kinase 1 (SphK1) inhibitor | ||
| 6038 | SR 10067 | Aug 2017 |
| Selective Rev-Erbα/β agonist; anxiolytic | ||
| 6138 | SR 9243 | Mar 2017 |
| Selective LXR inverse agonist | ||
| 6271 | ST 034307 | May 2017 |
| Adenylyl cyclase 1 (AC1) inhibitor; analgesic and active in vivo | ||
| 6036 | STK16-IN-1 | May 2017 |
| Serine/threonine protein kinase 16 (STK16) inhibitor; also inhibits PI 3Kδ, PI 3Kγ and mTOR kinases. | ||
| 5729 | TASP 0390325 | Apr 2017 |
| Potent and selective V1B receptor antagonist; orally bioavailable | ||
| 6227 | TAT-Gap19 | Apr 2017 |
| Cx43 hemichannel blocker | ||
| 6105 | TC AC 28 | Mar 2017 |
| High affinity BET bromodomain ligand | ||
| 6092 | TDZD 8 | Mar 2017 |
| Selective non-ATP competitive inhibitor of GSK 3β | ||
| 6191 | TH 1020 | Jul 2017 |
| Toll-like receptor (TLR) 5/Flagellin complex antagonist | ||
| 6194 | TM 5441 | Jun 2017 |
| Plasminogen activator inhibitor-1 (PAI-1) inhibitor | ||
| 5343 | TPPB | May 2017 |
| High affinity PKC activator; also APP modulator | ||
| 6311 | Tadalafil | May 2017 |
| Potent and highly selective PDE5 inhibitor; orally bioavailable | ||
| 5933 | Tocriscreen Kinase Inhibitor Toolbox I | Apr 2017 |
| A library of 80 kinase inhibitor compounds (250 μL 10 mM DMSO solutions) | ||
| 6268 | Tocriscreen Kinase Inhibitor Toolbox I & II | Apr 2017 |
| A library of 160 kinase inhibitor compounds (250 μL 10 mM DMSO solutions) | ||
| 6225 | Tocriscreen Kinase Inhibitor Toolbox II | Apr 2017 |
| A library of 80 kinase inhibitor compounds (250 μL 10 mM DMSO solutions) | ||
| 5932 | Tocriscreen Library of FDA-Approved Compounds | Mar 2017 |
| A library of 160 FDA-approved compounds (250 μL 10 mM DMSO solutions) | ||
| 6270 | Tubastatin A hydrochloride | Jun 2017 |
| Potent HDAC6 inhibitor | ||
| 4930 | UNC 2399 | Jun 2017 |
| Biotinylated UNC 1999 (Cat.No. 4904) | ||
| 6156 | VH 298 | Apr 2017 |
| High-affinity inhibitor of VHL | ||
| 6202 | Vilazodone hydrochloride | Apr 2017 |
| Potent 5-HT1A partial agonist and SSRI; antidepressant | ||
| 6061 | XMD 8-87 | May 2017 |
| Potent Ack1/TNK2 inhibitor | ||
| 6210 | ci-IP3/PM | Mar 2017 |
| Caged inositol triphosphate | ||
| 6155 | cis MZ 1 | Apr 2017 |
| Negative Control for MZ1 | ||
| 6157 | cis VH 298 | Apr 2017 |
| Negative control for VH 298 | ||
| 6286 | st-Ht31 | Jul 2017 |
| Inhibits PKA/AKAP interactions; cell permeable | ||
| 6287 | st-Ht31 P | Jul 2017 |
| Negative control for st-Ht31 (Cat. No. 6286) |